International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 4, Issue 8 | Case Report | Open Access
Houhong Wang*
Department of General Surgery, The Affiliated Bozhou Hospital of Anhui Medical University, China
*Correspondence to: Houhong Wang
Fulltext PDFGastric cancer (GC) is a highly malignant tumor with poor prognosis, and immunotherapy targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway has revolutionized its treatment. This retrospective study aimed to systematically evaluate the expression pattern, clinical associations, and prognostic significance of PD-L1 in GC using data from the PubMed database. We analyzed 42 eligible studies published between 2015 and 2024, involving 8,762 patients. Our results showed that PD-L1 expression was significantly higher in GC tissues compared to adjacent normal mucosa (pooled standardized mean difference [SMD] = 1.89, 95% confidence interval [CI]: 1.53-2.25, P < 0.001). High PD-L1 expression was associated with advanced TNM stage (odds ratio [OR] = 2.76, 95% CI: 2.14-3.56, P < 0.001), lymph node metastasis (OR = 2.93, 95% CI: 2.31-3.72, P < 0.001), and microsatellite instability-high (MSI-H) status (OR = 4.12, 95% CI: 3.28-5.17, P < 0.001). Moreover, elevated PD-L1 levels predicted shorter overall survival (hazard ratio [HR] = 1.68, 95% CI: 1.45-1.95, P < 0.001) in unselected patients, but correlated with better response to anti-PD-1/PD- L1 therapy (response rate: 42.3% vs. 15.6%, P < 0.001). These findings confirm that PD-L1 is a valuable biomarker for predicting GC prognosis and immunotherapeutic efficacy.
Houhong Wang. Analysis of Programmed Death-Ligand 1 (PD-L1) in Gastric Cancer. Int Clinc Med Case Rep Jour. 2025;4(8):1-4.